Korean biotech developing small-molecule kinase-inhibitor cancer drugs, licensing candidates to global and regional pharma partners.
Korean biotech developing small-molecule kinase-inhibitor cancer drugs, licensing candidates to global and regional pharma partners.
Its income comes from licensing fees and milestone payments received when partners pay for rights and development progress, so results depend on the timing of deal payments rather than steady sales.
Moat: narrow (IP / patents). AI-assisted drug-design platform generating novel kinase inhibitors licensed to partners.
Headquarters: Seoul, South Korea · Founded: 2015 · Employees: 149
Size Voronoi (310210.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 185th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩101,800 on 18 Nov 2026.
Performance Over six months the shares fell 61.9%, against -9.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 99.7% over the last twelve months (peer median +14.4%); the operating margin is -438,151.7% (peer median 10.9%).
Valuation It trades at 85,633.6× enterprise value to sales against a peer median of 3.9× (most expensive of 19).
Capital Return on invested capital runs 149.7 points below its cost of capital (7.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩22.1M | ₩7.51B | ₩0 | ₩0 | ₩9.77B |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | n/a | n/a | -₩1.97B | -₩2.71B | n/a |
| EBITDA | -₩94.2B | -₩52.6B | -₩34.4B | -₩28.6B | -₩15.5B |
| Net income | -₩85.8B | -₩42.7B | -₩32.6B | -₩36.8B | -₩19.9B |
| Free cash flow | -₩118B | -₩73.7B | -₩30.2B | -₩29.9B | -₩16.9B |
| Capital expenditure | ₩4.83B | ₩1.68B | ₩1.23B | ₩1.08B | ₩552M |
| Total debt | ₩17.8B | ₩39.8B | ₩990M | ₩12.3B | ₩25.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Voronoi 310210.KS | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a |
| Oscotec 039200.KS | $923M | -32% | +510% | 59% | 7.5× | -10.2% |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 310210.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.8% | -2.8% | 2nd lowest of 20 |
| 6-month return | -61.9% | -9.1% | 3rd lowest of 20 |
| Distance from 52-week high | -72.9% | -40.0% | 3rd lowest of 20 |
| Revenue growth (TTM) | -99.7% | +14.4% | lowest of 19 |
| Operating margin | -438,151.7% | 10.9% | lowest of 19 |
| EV / Sales | 85,633.6× | 3.9× | most expensive of 19 |
| ROIC minus cost of capital | -149.7 pp | -0.5 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |